NIH Funding

NIH Late Application Policy due to COVID-19

The NIH has announced their late application policy due to the evolving COVID-19 situation. In brief, the NIH will consider accepting late grant applications “on a case-by-case basis” and institutions must submit a cover letter of explanation.  

Please be aware that we are actively engaging in discussions with the NIH at this time. We will share any additional guidance we receive.

2021 Funding Opportunities for the NIH Director’s Transformative Award 

High-Risk, High-Reward Research Program
Summary: The program provides unique opportunities for exceptionally creative scientists to pursue highly innovative approaches to address major challenges in biomedical or behavioral research. Applications are welcome that propose any research topic relevant to the broad mission of NIH and from any eligible institution. NIH especially encourages applications from women and members of groups that are underrepresented in NIH-funded research.The NIH Common Fund encourages collaboration and supports a series of exceptionally high impact, trans-NIH programs.
The Transformative Research Award has separate funding opportunities available for COVID-19-related research to be supported by Emergency funds through the CARES Act. Applicants should apply to the appropriate funding opportunity based on their research topic. Applications submitted to the Emergency and non-Emergency funding opportunities will be reviewed together at the same time using the same process.
  • FY2021 NIH Director’s Transformative Research Award (R01 – Clinical Trial Optional): RFA RM-20-013
  • FY2021 NIH Director’s Emergency Transformative Research Award (R01 – Clinical Trial Optional): COVID-19 Proposals RFA RM-20-020



COVID-19 Funding Opportunities From the NIH:

  1. NIH “Notice of Special Interest: Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019”.
  2. The NIH also announced a “ Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need”.
  3. The NIH also issued a “Emergency Competitive Revision to Existing NIH Awards;”
  4. The NIH also issued a ““Notice of Special Interest regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 & Coronavirus Disease”;
  5. The NIH also announced “New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19”.
  6. The NIH also announced “NIH LATE APPLICATION POLICY Due to Public Health Emergency for United States for 2019 Novel Coronavirus”.
  7. The NIH also announced “Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19”.
  8. The NIH also announced “Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019”.
  9. The NIH published “General Frequently Asked Questions – Proposal Submission and Award Management Related to COVID-19”.
  10. Information for NIH Applicants and Recipients of NIH Funding 
  11. Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)